Findings of Scientific Misconduct, 120 [E5-8201]
Download as PDF
<![CDATA[
120
Federal Register / Vol. 71, No. 1 / Tuesday, January 3, 2006 / Notices
GOG group member at the University of
Iowa, in order to justify enrollment of a
patient in GOG clinical protocol 182.
The questioned research was
supported by National Institutes of
Health (NIH) funds to the University of
Iowa through the American Society for
Obstetrics and Gynecology under
National Cancer Institute (NCI),
National Institutes of Health (NIH),
cooperative agreement U10 CA27469.
Dr. Geisler has entered into a
Voluntary Exclusion Agreement
(Agreement ) in which he has
voluntarily agreed, for a period of three
(3) years, beginning on December 2,
2005:
(1) To exclude himself from serving in
any advisory capacity to PHS including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as consultant; and
(2) That any institution which uses
the Respondent in any capacity on PHSsupported research, or that submits an
application for PHS support for a
research project on which the
Respondent’s participation is proposed
or submits a report of PHS-funded
research in which the Respondent’s
participation is continuing, must
concurrently submit a plan for
supervision of the Respondent’s duties
to the funding agency for approval. The
supervisory plan must be designed to
ensure the scientific integrity of the
Respondent’s research contribution. A
copy of the supervisory plan must also
be submitted to ORI by the institution.
Respondent agrees that he will not
participate in any PHS-supported
research until such a supervision plan is
submitted to ORI.
Respondent disagrees with the ORI
finding set forth herein but executes this
Agreement to avoid further proceedings
and bring this matter to a close. The
execution of this Agreement shall not be
deemed an admission to the charge of
scientific misconduct by the
Respondent.
rmajette on DSK29S0YB1PROD with NOTICES6
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E5–8202 Filed 12–30–05; 8:45 am]
BILLING CODE 4150–31–P
VerDate Mar<15>2010
15:46 Nov 10, 2010
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
and the Acting Assistant Secretary for
Health have taken final action in the
following case:
Ralph A. Highshaw, M.D., M.D.
Anderson Cancer Center: Based on the
report of an investigation conducted by
the M.D. Anderson Cancer Center
(MDACC) and additional analysis
conducted by ORI in its oversight
review, the U.S. Public Health Service
(PHS) found that Ralph A. Highshaw,
M.D., Fellow, Department of Urologic
Surgery, MDACC, engaged in scientific
misconduct while supported by
National Cancer Institute (NCI),
National Institutes of Health (NIH),
postdoctoral training grant T32
CA079449–01A1.
Specifically, PHS found that Dr.
Highshaw engaged in scientific
misconduct by plagiarizing nine pages
of a twenty-one page expert review
article entitled ‘‘Chemoprevention of
Urologic Cancer.’’
Dr. Highshaw has entered into a
Voluntary Exclusion Agreement
(Agreement ) in which he has
voluntarily agreed, for a period of three
(3) years, beginning on December 12,
2005:
(1) That he is required to certify in
every PHS research application or
report, and any other text, article, or
manuscript, that all contributors are
properly cited or otherwise
acknowledged; the certification by the
Respondent must be endorsed by an
institutional official, and a copy of the
certification is to be sent to ORI by the
institution;
(2) To ensure that any institution
employing him submits, in conjunction
with each application for PHS funds,
annual reports, manuscripts, or abstracts
of PHS funded research in which the
Respondent is involved, a certification
that the data provided by the
Respondent are based on actual
experiments or are otherwise
legitimately derived, and that the data,
procedures, and methodology are
accurately reported in the application or
report; the Respondent must ensure that
the institution also sends a copy of the
certification to ORI; and
(3) To exclude himself from serving in
any advisory capacity to PHS including
SUMMARY:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E5–8201 Filed 12–30–05; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institute for Occupational
Safety and Health Advisory Board on
Radiation and Worker Health
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting:
Name: Advisory Board on Radiation
and Worker Health (ABRWH), National
Institute for Occupational Safety and
Health (NIOSH) and Subcommittee for
Dose Reconstruction and Site Profile
Reviews.
Subcommittee Meeting Time and
Date: 9 a.m.–5 p.m., January 24, 2006.
Committee Meeting Times and Dates:
8:30 a.m.–5 p.m., January 25, 2006. 8:30
a.m.–4:30 p.m., January 26, 2006.
Place: Doubletree Oak Ridge Hotel,
215 South Illinois Avenue, Oak Ridge,
Tennessee, 37830, telephone (865) 481–
2468, fax (865) 481–2474.
Status: Open to the public, limited
only by the space available. The meeting
space accommodates approximately 75
people.
Background: The ABRWH was
established under the Energy Employees
Occupational Illness Compensation
Program Act (EEOICPA) of 2000 to
advise the President, delegated to the
Secretary of Health and Human Services
(HHS), on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Board include
providing advice on the development of
probability of causation guidelines
which have been promulgated by HHS
as a final rule, advice on methods of
dose reconstruction which have also
been promulgated by HHS as a final
rule, advice on the scientific validity
and quality of dose estimation and
reconstruction efforts being performed
E:\FR\FM\03JAN1.SGM
03JAN1
]]>Agencies
[Federal Register Volume 71, Number 1 (Tuesday, January 3, 2006)]
[Notices]
[Page 120]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-8201]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Acting Assistant Secretary for Health have taken final
action in the following case:
Ralph A. Highshaw, M.D., M.D. Anderson Cancer Center: Based on the
report of an investigation conducted by the M.D. Anderson Cancer Center
(MDACC) and additional analysis conducted by ORI in its oversight
review, the U.S. Public Health Service (PHS) found that Ralph A.
Highshaw, M.D., Fellow, Department of Urologic Surgery, MDACC, engaged
in scientific misconduct while supported by National Cancer Institute
(NCI), National Institutes of Health (NIH), postdoctoral training grant
T32 CA079449-01A1.
Specifically, PHS found that Dr. Highshaw engaged in scientific
misconduct by plagiarizing nine pages of a twenty-one page expert
review article entitled ``Chemoprevention of Urologic Cancer.''
Dr. Highshaw has entered into a Voluntary Exclusion Agreement
(Agreement ) in which he has voluntarily agreed, for a period of three
(3) years, beginning on December 12, 2005:
(1) That he is required to certify in every PHS research
application or report, and any other text, article, or manuscript, that
all contributors are properly cited or otherwise acknowledged; the
certification by the Respondent must be endorsed by an institutional
official, and a copy of the certification is to be sent to ORI by the
institution;
(2) To ensure that any institution employing him submits, in
conjunction with each application for PHS funds, annual reports,
manuscripts, or abstracts of PHS funded research in which the
Respondent is involved, a certification that the data provided by the
Respondent are based on actual experiments or are otherwise
legitimately derived, and that the data, procedures, and methodology
are accurately reported in the application or report; the Respondent
must ensure that the institution also sends a copy of the certification
to ORI; and
(3) To exclude himself from serving in any advisory capacity to PHS
including but not limited to service on any PHS advisory committee,
board, and/or peer review committee, or as consultant.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E5-8201 Filed 12-30-05; 8:45 am]
BILLING CODE 4150-31-P
